Summit Therapeutics Inc. (SMMT) P/E Ratio History
Historical price-to-earnings valuation from 2018 to 2019
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Summit Therapeutics Inc. (SMMT) trades at a price-to-earnings ratio of -11.5x, with a stock price of $16.59 and trailing twelve-month earnings per share of $-1.44.
The current P/E is 144% below its 5-year average of 26.3x. Over the past five years, SMMT's P/E has ranged from a low of 12.4x to a high of 51.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, SMMT trades at a 149% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, SMMT trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SMMT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Vaccines and Infectious Disease peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
SCNIScinai Immunotherapeutics Ltd. | $3B | 0.1Lowest | -Best | +136% |
NVAXNovavax, Inc. | $2B | 3.9 | -Best | +310%Best |
CVACCureVac N.V. | $1B | 6.5 | -Best | +161% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2019 Q1 | $1.77 | $0.12 | 14.7x | -44% | |
| FY2018 Q4 | $1.33 | $0.11 | 12.4x | -53% | |
| FY2018 Q2 | $2.30 | $0.04 | 51.7x | +97% |
Average P/E for displayed period: 26.3x
See SMMT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SMMT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SMMT vs AGIO
See how SMMT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SMMT stock overvalued or undervalued?
SMMT trades at -11.5x P/E, below its 5-year average of 26.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SMMT's valuation compare to peers?
Summit Therapeutics Inc. P/E of -11.5x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is SMMT's PEG ratio?
SMMT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2018-2019.